Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eugene Zolotarevsky

Gastroenterology Traverse City, MI Medical Doctor

NPI 1508989633 CMS profile 890015

1105 Sixth St, Traverse City, MI 49684

Open in the dashboard

General payments

$23,709

71 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$10,500 paid to institutions, not to them · program years 2020–2022

Through program year 2025, Eugene Zolotarevsky of Traverse City, MI is reported in the CMS Open Payments database as having received $23,709 across 71 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $10,500 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 90th percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $524 7
2024 General $1,448 5
2023 General $9,490 19
2022 General $1,146 9
2021 General $8,961 14
2020 General $566 4
2019 General $1,574 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eugene Zolotarevsky
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Eugene Zolotarevsky were reported at $524. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Eugene Zolotarevsky Gastroenterology median Middle half National median
2019 $1,574 $417 $126–$1,100 $163
2020 $566 $224 $74–$624 $114
2021 $8,961 $352 $106–$1,054 $132
2022 $1,146 $448 $129–$1,270 $149
2023 $9,490 $533 $150–$1,390 $160
2024 $1,448 $605 $160–$1,606 $164
2025 $524 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $11,217 27 payments
  2. PENTAX of America, Inc. $8,643 15 payments
  3. Apollo Endosurgery US Inc $1,314 13 payments
  4. US Endoscopy $1,100 2 payments
  5. Steris Corporation $433 3 payments
  6. CSA Medical, Inc $371 1 payment
  7. Covidien LP $211 2 payments
  8. Olympus America Inc. $183 3 payments
  9. ERBE USA Inc $125 1 payment
  10. Mauna Kea Technologies, Inc. $50 1 payment
  11. Other $64 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $10,025 8 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,150 7 payments
  3. Food and Beverage $4,798 51 payments
  4. Travel and Lodging $706 3 payments
  5. Education $31 2 payments
Products named General payments · program years 2019–2025
  1. EXALT Model D EXALT Model D_ENDO $8,492 10 payments
  2. Aloka Arietta 850 $7,699 5 payments
  3. TruFreeze $1,533 5 payments
  4. GENERAL BILIARY DEVICES $984 3 payments
  5. Overstitch $652 5 payments
  6. OverStitch Endoscopic Suturing System $538 6 payments
  7. General - Therapies $300 1 payment
  8. N/A $283 2 payments
  9. EXALT Model D Exalt_Endo $274 3 payments
  10. Beacon $211 2 payments
  11. Other $1,825 24 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

350

Median for Gastroenterology: 569

Drug cost

$76,582

Median for Gastroenterology: $104,976

Branded share of claims

43.7%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 21 $67,491
Peg 3350-Electrolyte Sodium Chloride/Nahco3/Kcl/Peg Brand 99 $2,727
Omeprazole Generic 123 $2,187
Ursodiol Generic 14 $1,605
Pantoprazole Sodium Generic 60 $1,103
Lidocaine Hcl Viscous Lidocaine Hcl Brand 22 $739
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 11 $731

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 49 billing codes

Paid by Medicare

$77,360

Medicare's payments for the services billed

Medicare patients

218

Average age 73

Services billed

634

99 women, 119 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Diabetes 34%
Ischemic heart disease 32%
Depression 30%
COPD 29%
Atrial fibrillation 28%
Chronic kidney disease 28%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

71 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record